lulizumab pegol lulizumab pegol lulizumab pegol (inn; development code bms-931699) is a monoclonal antibody designed for the treatment of autoimmune diseases. lulizumab pegolmonoclonal antibodytype?sourcehumanizedtargetglycoprotein cd28clinical dataother namesbms-931699atc codenoneidentifierscas number1421830-13-8iuphar/bps8460chemspidernoneuniilct264ltyechemical and physical dataformulac552h859n149o164s4molar mass12335.06 g·mol−1 this drug was developed by bristol-myers squibb.